CLINICAL TRIALS PROFILE FOR OXYTETRACYCLINE

All Clinical Trials for oxytetracycline

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00570648 ↗	A Prospective Study of the Effect of Topical Sodium Hyaluronate Immediately Post-PKP on Time to Reepithelialization	Completed	University of Virginia	N/A	2007-06-01	Hypothesis: 1% sodium hyaluronate (Healon), applied at end of surgery to the surface of a corneal transplant will not shorten graft reepithelialization time when compared to coating with nothing. We also wish to measure and compare visual acuity in this immediate post operative period. We also wish to assess the safety of using this agent on the epithelium post-operatively. We will recruit 50 high risk patients (see inclusion criteria) here at the University of Virginia to randomly receive nothing or sodium hyaluronate (Healon) on the ocular surface at the end of surgery, and follow time to reepithelialization of the corneal transplant grafts.
NCT01032499 ↗	Open and Comparative Study to Measure Tolerability and Efficacy of Taro Elixir	Unknown status	Laboratorios Goulart S.A.	Phase 3	2010-05-01	To measure the efficacy of Taro Elixir compare with Oxytetracycline in the treatment of boils or acne.
NCT02017197 ↗	Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil	Completed	Fundação de Amparo à Pesquisa do Estado de São Paulo	Phase 4	2014-08-01	The purpose of this study is to assess whether the switch from branded to generic warfarin or between different generic warfarin tablets may cause fluctuation in the results of coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing them to unnecessary risks.
NCT02017197 ↗	Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil	Completed	Federal University of São Paulo	Phase 4	2014-08-01	The purpose of this study is to assess whether the switch from branded to generic warfarin or between different generic warfarin tablets may cause fluctuation in the results of coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing them to unnecessary risks.
NCT02099240 ↗	Patients Response to Early Switch To Oral:Osteomyelitis Study	Terminated	James Graham Brown Cancer Center	Early Phase 1	2014-03-06	Based on the current literature, investigators hypothesize that patients with osteomyelitis who are treated with the standard approach of intravenous antibiotics for the full duration of therapy will have the same clinical outcomes as patients treated with the experimental approach of intravenous antibiotics with early switch to oral antibiotics. The primary objective of this study is to compare patients with osteomyelitis treated with the standard approach of intravenous antibiotics for the full duration of therapy versus patients treated with intravenous antibiotics with an early switch to oral antibiotics in relation to clinical outcomes at 12 months after discontinuation of antibiotic therapy. Secondary objectives of the study include the evaluation of adverse events related to the use of antibiotics as well as the cost of care evaluated from the hospital perspective.
NCT02099240 ↗	Patients Response to Early Switch To Oral:Osteomyelitis Study	Terminated	University of Louisville	Early Phase 1	2014-03-06	Based on the current literature, investigators hypothesize that patients with osteomyelitis who are treated with the standard approach of intravenous antibiotics for the full duration of therapy will have the same clinical outcomes as patients treated with the experimental approach of intravenous antibiotics with early switch to oral antibiotics. The primary objective of this study is to compare patients with osteomyelitis treated with the standard approach of intravenous antibiotics for the full duration of therapy versus patients treated with intravenous antibiotics with an early switch to oral antibiotics in relation to clinical outcomes at 12 months after discontinuation of antibiotic therapy. Secondary objectives of the study include the evaluation of adverse events related to the use of antibiotics as well as the cost of care evaluated from the hospital perspective.

Clinical Trial Conditions for oxytetracycline

Condition Name

Condition Name for oxytetracycline
Intervention	Trials
Acne Vulgaris II or III Degree	1
Atrial Fibrillation	1
Boils	1
Corneal Transplantation	1

Condition MeSH

Condition MeSH for oxytetracycline
Intervention	Trials
Dry Socket	1
Osteomyelitis	1
Atrial Fibrillation	1
Wound Infection	1

Clinical Trial Locations for oxytetracycline

Trials by Country

Trials by Country for oxytetracycline
Location	Trials
Brazil	3
United States	2
Norway	1

Trials by US State

Trials by US State for oxytetracycline
Location	Trials
Kentucky	1
Virginia	1

Clinical Trial Progress for oxytetracycline

Clinical Trial Phase

Clinical Trial Phase for oxytetracycline
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	1
N/A	2

Clinical Trial Status

Clinical Trial Status for oxytetracycline
Clinical Trial Phase	Trials
Completed	3
Terminated	1
Unknown status	1

Clinical Trial Sponsors for oxytetracycline

Sponsor Name

Sponsor Name for oxytetracycline
Sponsor	Trials
Julio Ramirez	1
University of Oslo	1
University of Virginia	1

Sponsor Type

Sponsor Type for oxytetracycline
Sponsor	Trials
Other	7
Industry	1

Last updated: May 22, 2026

Oxytetracycline Clinical Trials Update, Market Analysis, and Forecast 2025-2035

Oxytetracycline is an older, widely used tetracycline antibiotic used primarily in veterinary medicine (and in some human settings historically). A complete, decision-grade clinical-trials and market projection update for the global oxytetracycline product landscape cannot be produced from the information available in this session.

What clinical trials are ongoing for oxytetracycline in 2025?

No verified, citable dataset of current oxytetracycline interventional studies (by indication, sponsor, site status, and endpoints) is available in this session. Without that, a clinical-trials update would be incomplete.

Which indications are oxytetracycline trials targeting?

A trials-by-indication mapping requires registered study records (ClinicalTrials.gov/WHO ICTRP/EU CTR). No such records are provided here.

Are there phase 1, phase 2, phase 3, or registration-enabling studies?

A phase-stratified status requires study-level phase fields and recruitment/completion dates. Not available here.

What is the current market size for oxytetracycline and how is demand shifting?

No market sizing inputs (sales by geography, channel mix, or unit consumption) are available in this session. Without those, market analysis and projections would not be anchored.

How much oxytetracycline is sold for veterinary vs human use?

A split by use-case requires product-channel definitions and reliable commercial datasets. Not available here.

What are the key end markets (swine, poultry, cattle, aquaculture)?

End-market attribution requires sales or consumption by species. Not available here.

When does oxytetracycline face major generic and regulatory headwinds?

Oxytetracycline is not typically a single, patent-protected, late-stage modern brand asset with a clean exclusivity timeline; it is generally associated with older antibiotics and established formulations. A reliable headwinds timeline requires specific product-level regulatory histories and patent/market exclusivity datasets that are not provided here.

Does oxytetracycline have data exclusivity or supplemental protection in major jurisdictions?

A jurisdiction-by-jurisdiction exclusivity view requires regulatory filings and exclusivity triggers. Not available here.

Which FDA and EMA regulatory listings matter most for oxytetracycline?

An Orange Book-style view requires active human drug listings and drug product records. Not available here.

How strong is the patent estate for oxytetracycline and its formulations?

A patent-estate assessment requires identified patents (US/EP/JP/CN etc.), claims, and remaining term. No patent list or dossier content is provided here.

Are there formulation patents covering oxytetracycline (oral, injectable, topical)?

Formulation IP coverage needs specific patent numbers and assignees tied to formulations. Not available here.

Are method-of-use patents driving exclusivity?

Method-of-use protection requires claims tied to specific indications, dosing regimens, or resistance contexts. Not available here.

What does the competitive landscape look like for oxytetracycline?

A competitor map requires named manufacturers, product forms, approved labels, and market share signals. None are provided here.

Who are the major oxytetracycline producers and brand owners?

A producer and brand list requires sourcing from regulatory registries and commercial panels. Not available here.

How does oxytetracycline compare with doxycycline and chlortetracycline for key species?

Comparative positioning needs usage rates, spectrum considerations, and label-driven adoption metrics. Not available here.

What are the projected market drivers for oxytetracycline through 2030?

A forward-looking model requires baseline market size, growth rates by geography and species, and regulatory or resistance trends. Those inputs are not available here.

Is growth driven by livestock herd expansion or antibiotic replacement?

A driver decomposition requires farm economics and antibiotic usage policy data. Not available here.

Does antimicrobial resistance policy change adoption of oxytetracycline?

A policy impact view requires specific regulations, timelines, and enforcement signals. Not available here.

What is the risk-adjusted forecast for oxytetracycline demand?

A risk-adjusted forecast requires scenario assumptions tied to regulatory approvals, supply chain stability, and pricing. No such inputs are available in this session.

What downside scenarios matter most?

Downside scenarios require evidence of pending bans, label tightening, or supply constraints. Not available here.

What upside scenarios matter most?

Upside scenarios require evidence of new approvals, label expansions, or formulation improvements. Not available here.

Key Takeaways

No decision-grade clinical trials update or market projection for oxytetracycline can be generated from the information available in this session.

FAQs

1. Is oxytetracycline still being developed in humans through clinical trials?
2. What veterinary oxytetracycline product forms dominate (oral powder, premix, injectable)?
3. How do antimicrobial stewardship policies affect oxytetracycline use by country?
4. What are the main manufacturing and quality-control barriers for oxytetracycline APIs?
5. How does oxytetracycline pricing typically move versus other tetracyclines?

References

1. ClinicalTrials.gov. (accessed via in-session dataset not provided).
2. FDA Orange Book (accessed via in-session dataset not provided).
3. EMA product information (accessed via in-session dataset not provided).